WHO Biowaiver Project Cycle VII (2025) and Results from Cycle VI (2024)
Recommendation
3/4 February 2026
Evaluation, Implementation and Use of Suitable Technologies
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The World Health Organization (WHO) has published a draft working entitled WHO Biowaiver Project - Prioritization exercise of active pharmaceutical ingredients for cycle VII (2025) and preliminary results from cycle VI (2024) (QAS/24.966).
Biowaivers are a way of waiving bioequivalence studies in human, which means that they are not considered necessary for product approval. This document is intended to support the prioritization exercise of APIs to be characterized in their solubility profile in cycle VII of the WHO Biowaiver Project and present the preliminary results from cycle VI.
Content of the Document
The working document starts with a brief background section, providing an overview of the project’s development. The main document is divided into the following three sections:
- Introduction
- The revised WHO Biowaiver List
- Prioritization exercise of active pharmaceutical ingredients for Biopharmaceutical Classification System-based classification in WHO Biowaiver Project
This is followed by a list of references and further reading.
The document was posted on the WHO Medicines website under "Working documents in public consultation".
Related GMP News
12.01.2026FDA Warning Letter: OOS Handling and HPLC Method Validation
12.01.2026Eurachem Publishes New Guide on the Fitness for Intended Use of Analytical Equipment and Systems
07.01.2026Revised Ph. Eur. Chapters 2.9.42 and 2.9.43 on Dissolution Testing
07.01.2026Korean MFDS Publishes Data Collection on Dissolution Test Methods
18.12.2025FDA Form 483: Excel-Based Data Falsification and Duplicate Log Books
18.12.2025Questions and Answers on System Suitability Tests (SST) - Part 1